Nov 8, 2021 4:05pm EST Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the American College of Rheumatology Convergence 2021
Nov 8, 2021 7:00am EST Tonix Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights
Oct 15, 2021 7:00am EDT Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Infectious Disease R&D Center in Maryland
Oct 7, 2021 7:00am EDT Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
Oct 4, 2021 7:00am EDT Tonix Pharmaceuticals Announces Completion of Acquisition of Infectious Disease R&D Center in Frederick, Maryland
Sep 27, 2021 7:00am EDT Tonix Pharmaceuticals Announces Oral Presentation at the American College of Rheumatology Convergence 2021
Sep 23, 2021 7:00am EDT Tonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
Sep 22, 2021 7:00am EDT Tonix Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
Sep 13, 2021 8:00am EDT Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19
